Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015
Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 22992568; or from the webcast link in the investor relations section of the Company’s website at: www.revance.com.
A replay of the call will be available beginning
About
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance’s proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights
for all indications of RT001, RT002 and the TransMTS technology platform. More information on
“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of
CONTACT: Investor ContactRevance Therapeutics Jeanie Herbert (714) 325-3584 jherbert@revance.comWestwicke Partners Leigh Salvo (415) 513-1281 leigh.salvo@westwicke.comleigh.salvo@westwicke.com Trade Media Contact Nadine Tosk (847) 920-9858 nadinepr@gmail.com
Source:
News Provided by Acquire Media